FY2026 Earnings Estimate for Arvinas Issued By HC Wainwright

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at HC Wainwright issued their FY2026 EPS estimates for Arvinas in a report issued on Tuesday, November 3rd. HC Wainwright analyst A. Maldonado expects that the company will earn $0.00 per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Arvinas’ Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.44) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($0.72) EPS.

Several other equities research analysts have also recently weighed in on the company. Zacks Research upgraded Arvinas from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 9th. Wedbush lifted their price target on Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Wells Fargo & Company cut Arvinas from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $15.00 to $11.00 in a report on Tuesday, August 4th. Wall Street Zen raised Arvinas from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Morgan Stanley set a $10.00 target price on Arvinas in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.18.

Arvinas Trading Up 4.7%

NASDAQ ARVN opened at $7.42 on Thursday. The firm’s 50 day simple moving average is $7.98 and its 200 day simple moving average is $9.63. The firm has a market capitalization of $478.75 million, a price-to-earnings ratio of -30.92 and a beta of 1.81. Arvinas has a 1 year low of $6.74 and a 1 year high of $14.51.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10. Arvinas had a negative net margin of 3.45% and a negative return on equity of 2.06%. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $12.39 million. During the same period in the previous year, the company earned ($0.48) EPS. The business’s revenue for the quarter was down 98.8% compared to the same quarter last year.

Institutional Trading of Arvinas

A number of hedge funds have recently added to or reduced their stakes in ARVN. BlackRock Inc. bought a new stake in shares of Arvinas during the second quarter worth $63,232,000. Dimensional Fund Advisors LP lifted its stake in shares of Arvinas by 2.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 485,764 shares of the company’s stock valued at $5,147,000 after acquiring an additional 13,344 shares during the last quarter. Algert Global LLC lifted its stake in shares of Arvinas by 137.6% in the 2nd quarter. Algert Global LLC now owns 426,415 shares of the company’s stock valued at $3,544,000 after acquiring an additional 246,919 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Arvinas in the 2nd quarter valued at $2,493,000. Finally, Brummer Multi Strategy AB boosted its holdings in shares of Arvinas by 71.4% during the 1st quarter. Brummer Multi Strategy AB now owns 285,076 shares of the company’s stock valued at $3,022,000 after acquiring an additional 118,734 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, implying about 75% upside from the cited $7.42 share price. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 data for ARV-393 at the 2026 American Society of Hematology meeting. The presentation could provide a clinical catalyst, though the report does not disclose results yet. Arvinas to Present Preliminary ARV-393 Clinical Data
• Negative Sentiment: Recent quarterly results showed revenue of just $0.5 million, far below the $12.39 million analyst estimate and down 98.8% year over year. The $0.82-per-share loss was better than the consensus loss estimate, but wider than the year-ago loss. Arvinas Reports Third Quarter 2026 Results
• Negative Sentiment: HC Wainwright’s estimates anticipate losses in 2027–2030, including a $2.44-per-share loss in 2027, underscoring the company’s ongoing path to profitability risk despite the bullish rating.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.